Samsung Biologics and Lotte Biologics took part side by side in "DCAT Week," a global pharmaceutical and biotech industry business event held in New York from the 23rd to the 26th.
DCAT Week is a leading international exchange event in the pharmaceutical and biotech industry held annually in New York. Global pharmaceutical companies and contract development and manufacturing organizations (CDMOs) participate in large numbers to seek collaboration opportunities.
The fact that this year's venue is the Lotte New York Palace (LotteNewYorkPalace) hotel is meaningful for Lotte Biologics as well. Both companies have set up dedicated meeting rooms at the venue and are aiming for opportunities to collaborate in the CDMO business.
Samsung Biologics said it plans to hold more than 50 business meetings with global pharmaceutical companies. Chief Executive John Rim, who has attended DCAT Week for four consecutive years since 2023, is focusing on promoting differentiated CDMO competitiveness and expanding global business that leads to tangible contract signings and new client acquisition.
On the first day of the event, Kevin Scharp, head of sales and operations at the commercial center, joined the member company presentation forum as a speaker and shared outcomes including the open innovation partnership with Eli Lilly and the vaccine manufacturing partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).
Lotte Biologics is focusing on CDMO partnership talks by highlighting the synergy between the accumulated quality competitiveness of the Syracuse Bio Campus in New York and the large-scale manufacturing capacity of the first plant at the Songdo Bio Campus in Incheon, slated for completion in Aug.
Lotte Biologics also introduced that, through its collaboration with ASIMOV, with which it signed a business agreement in Mar. last year, it can carry out work from cell line development to drug substance manufacturing within about 8.5 months. It also emphasized that it provides development and manufacturing support for a variety of modalities, including monoclonal antibodies and Bispecific Antibody, and offers step-by-step manufacturing options spanning from clinical stages to Good Manufacturing Practice (GMP) licensed production.